Gilla Kaplan Biography and Net Worth

Director of Tyra Biosciences

Gilla Kaplan, Ph.D. is the Chief Executive Officer of Gilrose Therapeutics and a Senior Advisor of Medicine Development for Global Health. Before Gilrose, Dr. Kaplan was Senior Advisor at the Bill and Melinda Gates Medical Research Institute (Gates MRI) and the Director of the Global Health Program, Tuberculosis of the Bill and Melinda Gates foundation (BMGF). She has spent her career as an academic research scientist leading a laboratory in investigations focusing on human disease, exploring novel experimental medicine approaches that modulate the immune response for disease control. She was a recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan currently serves on the board of directors of Cerecor. She previously served on the board of directors at Celgene for 20 years. Dr. Kaplan received a Bachelor of Science degree from Hebrew University, Jerusalem, Israel and a Master of Science and Ph.D. in Cellular Immunology from University of Tromso, Norway.

What is Gilla Kaplan's net worth?: The estimated net worth of Gilla Kaplan is at least $624.19 thousand as of June 18th, 2025. Dr. Kaplan owns 28,231 shares of Tyra Biosciences stock worth more than $624,187 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Kaplan may own. Learn More about Gilla Kaplan's net worth.
How do I contact Gilla Kaplan?: The corporate mailing address for Dr. Kaplan and other Tyra Biosciences executives is 2656 STATE STREET, CARLSBAD CA, 92008. Tyra Biosciences can also be reached via phone at 619-728-4760 and via email at [email protected].. Learn More on Gilla Kaplan's contact information.
Has Gilla Kaplan been buying or selling shares of Tyra Biosciences?: Gilla Kaplan has not been actively trading shares of Tyra Biosciences over the course of the past ninety days. Most recently, Gilla Kaplan sold 9,568 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a transaction totalling $93,575.04. Following the completion of the sale, the director now directly owns 28,231 shares of the company's stock, valued at $276,099.18. Learn More on Gilla Kaplan's trading history.
Who are Tyra Biosciences' active insiders?: Tyra Biosciences' insider roster includes Daniel Bensen (COO), Alan Fuhrman (CFO), Todd Harris (CEO), and Gilla Kaplan (Director). Learn More on Tyra Biosciences' active insiders.
Are insiders buying or selling shares of Tyra Biosciences?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 330,261 shares worth more than $5,972,313.26. The most recent insider tranaction occured on November, 21st when Director Robert J More sold 246,871 shares worth more than $4,999,137.75. Insiders at Tyra Biosciences own 15.2% of the company. Learn More about insider trades at Tyra Biosciences.
Information on this page was last updated on 11/21/2025.

Gilla Kaplan Insider Trading History at Tyra Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/18/2025	Sell	9,568	$9.78	$93,575.04	28,231
6/17/2025	Sell	10	$10.35	$103.50	37,799
6/16/2025	Sell	6,814	$10.38	$70,729.32	37,809
6/13/2025	Sell	15,000	$10.31	$154,650.00	44,623
6/12/2025	Sell	30,000	$10.31	$309,300.00	59,623

Gilla Kaplan Buying and Selling Activity at Tyra Biosciences

Tyra Biosciences Company Overview

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Today's Range

Now: $22.11

$21.43

$22.13

50 Day Range

MA: $16.14

$12.97

$22.51

2 Week Range

Now: $22.11

$6.42

$22.83

Volume

916,903 shs

Average Volume

466,587 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09